Verici Dx plc (AIM:VRCI)
London
· Delayed Price · Currency is GBP · Price in GBX 1.125
0.00 (0.00%)
Jul 11, 2025, 3:37 PM GMT+1
Verici Dx Revenue
In the year 2024, Verici Dx had annual revenue of $3.34M USD with 229.62% growth.
Revenue
$3.34M
Revenue Growth
+229.62%
P/S Ratio
1.02
Revenue / Employee
$238.50K
Employees
14
Market Cap
2.73M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.34M | 2.33M | 229.62% |
| Dec 31, 2023 | 1.01M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 42.56B |
| GSK plc | 31.53B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Genus | 671.60M |
Verici Dx News
- 2 months ago - AIM Market Roundup: Belluscura, Tiger Royalties, ITM Power - The Armchair Trader
- 3 months ago - AIM Market Roundup: Ethernity Networks, Verici DX, Aferian - The Armchair Trader
- 3 months ago - AIM Market Roundup: Rome Resources, Celadon Pharmaceuticals, Churchill China - The Armchair Trader
- 3 months ago - AIM Market Roundup: Celadon Pharma, Oracle Power, Volex - The Armchair Trader
- 7 months ago - FBB Biomed Signs Agreement with Verici Dx plc to Offer Research-Use-Only “RUO” Tests to Clinicians - Business Wire